慢性淋巴细胞白血病患者对SARS-CoV-2疫苗的体液和细胞免疫应答减弱
这项美国11家癌症中心的国家级协作研究纳入初始接种队列210例和加强接种队列117例慢性淋巴细胞白血病患者,评估SARS-CoV-2 mRNA疫苗诱导的血清学和T细胞应答。初始队列抗S血清转化率为56%(95%CI 50-63),加强队列为68%(95%CI 60-77);接受B细胞靶向治疗者较未治疗者血清转化可能性更低(OR 0.27;95%CI 0.15-0.49)。
要点
- 初始接种队列210例抗S血清转化率56%(95%CI 50-63),加强接种队列117例为68%(95%CI 60-77)。
- 接受B细胞靶向治疗者较未治疗者血清转化可能性更低(OR 0.27;95%CI 0.15-0.49)。
- 初始队列血清学应答与CD4 T细胞应答正相关(Wuhan变异Spearman P=0.45;Omicron变异P=0.25)。
核心结论
- 慢性淋巴细胞白血病患者对SARS-CoV-2 mRNA疫苗的血清转化率较低,接受B细胞靶向治疗者血清转化可能性更低。
- 加强接种后抗S滴度升高,且未报告加强接种后COVID-19死亡病例,但患者应保持谨慎,因新变异株出现并可逃逸疫苗诱导免疫。
研究设计与样本
- 美国11家癌症中心的国家级协作研究(#NCT04852822)。
- 符合条件患者纳入2个队列:初始接种时队列和加强接种时队列。
- 初始接种队列210例,加强接种队列117例。
主要发现
- 初始接种队列210例抗S血清转化率为56%(95%CI 50-63),加强接种队列117例为68%(95%CI 60-77)。
- 接受B细胞靶向治疗者较未治疗者血清转化可能性更低(OR 0.27;95%CI 0.15-0.49)。
- 应答在6个月时持续存在;给予加强接种后抗S滴度升高。
- 初始接种队列中,定量血清学应答与CD4 T细胞应答在Wuhan变异呈正相关(Spearman P=0.45),在Omicron变异相关性较低(P=0.25)。
- 加强接种队列中,血清学应答与CD4 T细胞应答在Wuhan变异(P=0.58)和Omicron变异(P=0.57)均呈正相关,与CD8 T细胞应答相关性较低(Wuhan P=0.33;Omicron P=0.22)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Previous studies have demonstrated low rates of seroconversion to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccines in patients with chronic lymphocytic leukemia (CLL). In this national collaboration of 11 cancer centers in the United States, we aimed to further characterize and understand vaccine-induced immune responses, including T-cell responses, and the impact of CLL therapeutics (#NCT04852822). Eligible patients were enrolled in 2 cohorts (1) at the time of initial vaccination and (2) at the time of booster vaccination. The serologic response rates (anti-S) from 210 patients in the initial vaccination cohort and 117 in the booster vaccination cohort were 56% (95% confidence interval [CI], 50-63) and 68% (95% CI, 60-77), respectively. Compared with patients not on therapy, those receiving B-cell-directed therapy were less likely to seroconvert (odds ratio [OR], 0.27; 95% CI, 0.15-0.49). Persistence of response was observed at 6 months; anti-S titers increased with the administration of booster vaccinations. In the initial vaccination cohort, positive correlations were observed between the quantitative serologic response and CD4 T-cell response for the Wuhan variant and, to a lesser degree, for the Omicron variant (Spearman P = 0.45 Wuhan; P = 0.25 Omicron). In the booster vaccination cohort, positive correlations were observed between serologic responses and CD4 T-cell responses for both variants (P = 0.58 Wuhan; P = 0.57 Omicron) and to a lesser degree for CD8 T-cell responses (P = 0.33 Wuhan; P = 0.22 Omicron). Although no deaths from coronavirus disease 2019 (COVID-19) have been reported after booster vaccinations, patients should use caution as newer variants emerge and escape vaccine-induced immunity. This trial was registered at www.clinicaltrials.gov as #NCT04852822.
引用
- Ujjani C, Gooley TA, Spurgeon SE, et al. Diminished humoral and cellular responses to SARS-CoV-2 vaccines in patients with chronic lymphocytic leukemia. Blood Adv. 2023. PMID: 36516082. doi:10.1182/bloodadvances.2022009164
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。